Exact Sciences' COLOGUARD was recommended by an FDA Advisory Panel on March 27th with unanimous 10-0 approval on all 3 questions concerning safety, effectiveness, and benefits vs risks.
Company issued 10 million shares of stock at $12.75 and now has $250 million in cash on the balance sheet...